The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
This Centre of Research Excellence will translate the best available evidence to improve cancer outcomes through better management of infections in cancer patients, a rapidly growing group. We will establish new research networks to detect emerging multi resistant infections, develop guidelines on how to manage them, implement locally successful programs that have been shown to save lives nationally and validate new practice changing immune, bioinformatics and diagnostic technologies.
Air Pollution And Mortality And Morbidity In Adult Australians (APMMA Study): A Large Population Based Cohort Study
Funder
National Health and Medical Research Council
Funding Amount
$1,041,410.00
Summary
This study will investigate the link between respiratory and cardiovascular disease and mortality and exposure to long-term air pollution. We will use cutting edge methods to assign neighbourhood air pollution levels to a large cohort of NSW adults (n>265,000) previously recruited in the 45 and Up Study. The study results will be of utmost importance in setting outdoor air pollution standards and informing cost benefit analyses of air pollution control strategies.
Rapidly giving intravenous fluid to prevent or treat shock (fluid resuscitation) is one of the commonest treatments given to critically ill patients. Current guidelines recommend crystalloid solutions but it is unknown whether any particular crystalloid is better than others. This trial will determine whether the use of one of two crystalloid fluids, saline or PlasmaLyte, reduces the risk of organ injuries, such as kidney failure, and improves patients chances of surviving critically illness.
Assessing The Benefit Of Low Dose Aspirin In The Prevention Of Severe Sepsis.
Funder
National Health and Medical Research Council
Funding Amount
$391,880.00
Summary
Recent discoveries suggest that low doses of aspirin may save lives in patients with infection by limiting its severity. We will conduct a large-scale primary prevention study using daily low-dose aspirin to explore whether this widely used drug can safely prevent severe infection. This study is made possible by collaborative involvement in an existing Australian and USA funded study called ASPREE. Finding a treatment that helps prevent severe effects and outcomes of infection would be a major h ....Recent discoveries suggest that low doses of aspirin may save lives in patients with infection by limiting its severity. We will conduct a large-scale primary prevention study using daily low-dose aspirin to explore whether this widely used drug can safely prevent severe infection. This study is made possible by collaborative involvement in an existing Australian and USA funded study called ASPREE. Finding a treatment that helps prevent severe effects and outcomes of infection would be a major health advance.Read moreRead less
About 14,000 cases of bowel cancer occur annually in Australia despite the availability of life-saving screening. Most people do not receive recommended screening colonoscopy. We will look at why people at high-risk avoid screening and why people at average risk seek unnecessary screening. We will analyse family history and contacts with the healthcare system that impact screening decisions. We will determine the impact of screening on reducing the number of new cases and deaths.
Antagonist Of Corticotrophin Releasing Hormone As Therapeutic Agents For The Prevention Of Premature Birth In Humans
Funder
National Health and Medical Research Council
Funding Amount
$376,650.00
Summary
In developed countries the most common cause of the death of a newborn baby is premature delivery. Pre-term delivery remains the greatest cause of neonatal mortality in the western world and a major consumer of health dollars (approx. $5-7B per year in the US alone). However, a delay in the onset of labour from 20 to 25 weeks has been shown to result in a 55% greater probability of infant survival (550 fewer deaths per 1000). This project will allow: The development of new drugs that will allow ....In developed countries the most common cause of the death of a newborn baby is premature delivery. Pre-term delivery remains the greatest cause of neonatal mortality in the western world and a major consumer of health dollars (approx. $5-7B per year in the US alone). However, a delay in the onset of labour from 20 to 25 weeks has been shown to result in a 55% greater probability of infant survival (550 fewer deaths per 1000). This project will allow: The development of new drugs that will allow the extension of pregnancy term The development of protocols that will in turn reduce neonatal mortality. Additionally we believe that these new agents will be useful in preventing the onset of labour after fetal surgery. Currently there are no effective treatments capable of substantially changing delivery dates. Available therapeutics delay the onset of labour, at best, 24 hours. However, recent exciting results from our laboratories show that rising concentrations of the placental peptide Corticotrophin Releasing Hormone (CRH) are associated with the onset of labour. Further, we have also delayed the onset of labour in pregnant sheep by infusing a relatively insoluble CRH antagonist into the sheep fetus. Labour commenced ONLY AFTER the drug was withdrawn from the mother. This project builds upon an interdisciplinary team: medicinal chemists, molecular modellers, pharmacologists and endocrinologists, to further develop an exciting Australian discovery. Successful completeion of this research will, for the first time, allow the control of pregnancy duration MAXIMISING the benefits to mother and child, reducing mortality and later life morbidities typically associated with premature birth.Read moreRead less
A Community-based Cluster Randomized Controlled Trial In Rural Bangladesh To Evaluate The Impact Of The Use Of Iron/folic Acid Supplements Early In Pregnancy On The Risk Of Neonatal MortalityBACKGROUND An Effective Program Of Antenatal Iron/folic Ac
Funder
National Health and Medical Research Council
Funding Amount
$2,564,922.00
Summary
This community-based trial in rural Bangladesh will determine if iron/folic acid supplementation commencing in the first trimester of pregnancy significantly reduces newborn deaths, and whether this approach is cost-effective. This trial has the potential to inform international public health policy about the importance of starting antenatal iron/folic acid supplementation early to improve neonatal survival, and to help countries reach their child survival Millennium Development Goal
Identification of genes regulating breast cancer progression and metastasis. Breast cancer is the most common cause of cancer-related death in women in Australia. Although the treatments have improved over the last thirty years, many women still die from relapse of the disease. Our goal is to identify genes involved in the regulation of breast cancer progression and metastasis. This may lead to the discovery of druggable molecules for better targeted therapies for patients.
The role of P2X7 and P2X4 receptor mediated innate phagocytosis in pathogenesis and treatment of neurodegenerative diseases. This project will identify how inherited variation in two proteins of the brain can accelerate the removal of neurones and predispose to a range of neurodegenerative diseases. Knowledge of the biological basis of this finding will allow a search for new compounds which will slow and protect against this form of neurodegeneration.
Identifying mitogenic signalling proteins with phosphatidyl inositol lipids. Health care of an ageing population is a national priority of the community. In order to understand the factors that control cell growth and death in cancer cells signalling proteins can be identified and studied and compared with model systems from quiescent cells. Using phospholipids attached to 'fishing lines' we can search for, identify and study the function of all the downstream signalling proteins in activated c ....Identifying mitogenic signalling proteins with phosphatidyl inositol lipids. Health care of an ageing population is a national priority of the community. In order to understand the factors that control cell growth and death in cancer cells signalling proteins can be identified and studied and compared with model systems from quiescent cells. Using phospholipids attached to 'fishing lines' we can search for, identify and study the function of all the downstream signalling proteins in activated cancer cells. This will provide the basic information for drug discovery processes to target specific molecules that inhibit and control the function of the signalling proteins implicated in the growth of cancer cells.Read moreRead less